



Breaking news

HealthTech For Care, its sponsors, and supporters adapt the 5th edition of HealthTech Innovation Days to the uncertain economic and financial context in Europe.

The development of medical innovation for the benefit of European patients is going through uncertain financial times. The economic impact on the development of European HealthTech companies is a real challenge. In order to support medical innovation for the benefit of patients, HealthTech For Care, its sponsors and supporters are providing a concrete solution for these companies through HealthTech Innovation Days (HTID), by modifying the participation criteria for companies, in order to welcome early-stage companies.

Paris, France, June 27, 2023 - The HealthTech For Care endowment fund, which aims to promote access to care for patients, has chosen to open the 5th edition of HealthTech Innovation Days (HTID[®]) to early-stage European companies. This decision was taken in conjunction with its sponsors from the healthcare ecosystem: leading pharmaceutical companies, industry players, specialist consultancies and investors in healthcare technologies, and institutional partners, as well as its supporters: European clusters and patient associations.

The macro-economic and financial context in Europe for the HealthTech sector remains uncertain, with funding for companies in the ecosystem plummeting worldwide from €55 billion in 2021 to €30 billion in 2022.

While innovation in healthcare remains dynamic, early-stage HealthTech companies are at risk of not receiving the support they need to develop, whether in the form of funding and/or partnerships. This could delay or even halt the development of solutions for patients. To encourage these developments, HTID's participation criteria are evolving to welcome companies at the proof-of-concept stage whose:

- **Biotechs** developing a treatment currently undergoing in-vivo evaluation, close to applying to regulatory agencies for entry into the clinic.
- **Medtechs** with a prototype in the patient testing phase.
- **Innovative services companies** developing innovative products and services for players in the healthcare sector.
- **Digital Health** with a solution under development with partners such as hospitals, pharmaceutical or industrial companies.

Maryvonne Hiance, President of HealthTech For Care says: "We have become aware of the difficulty of financing companies in Europe. As a public-interest endowment fund, we want to promote access to healthcare for all, and support all innovative companies, whether early-stage or more mature, so that their solutions are available as quickly as possible for the benefit of patients. We hope that this approach will support the dynamic of innovation for the entire healthcare ecosystem in Europe."

The 5th edition of HTID[®] benefits from the support of numerous sponsors: <u>Alira Health</u>, <u>Amgen France</u>, <u>Bnpparibas</u>, <u>bpifrance</u>, <u>Cepton Strategies - Vintura</u>, <u>Euronext</u>, <u>Icosa</u>, <u>Invest Securities</u>, <u>Ipsen</u>, <u>Life</u> <u>Sciences Acceleration Alliance</u>, <u>Mapi Research Trust</u>, <u>McDermott Will & Emery</u>, <u>Peak Lifecycles</u>, <u>Servier</u>, <u>Sofinnova Partners</u> HealthTech For Care is supported by its founder France Biotech and the network of French healthcare clusters: Atlanpole biotherapies, BioValley France, EuroBioMed, LyonBioPole, Medicen and the clubster NHL. The endowment fund is also supported by numerous European players: Asebio, BioAlps, BIO Deutschland, BIA, BioWin, CEBR, Federchimica Assobiotec, flanders.bio, HollandBIO, IREFI, Medvia, MedTech Europe, Swiss Biotech, and Technion France.

Registration link for HealthTech early-stage companies: https://www.surveymonkey.com/r/htid5-application

The HealthTech Innovation Days (HTID[®]) are held under the High Patronage of Mr Emmanuel MACRON, President of the French Republic, with the participation of the European Commission and the European Investment Bank (EIB). HTID[®] provides a forum for promising European life sciences companies to accelerate their growth and bring their solutions to patients faster. It combines :

- **One-to-one meetings** between innovative European healthcare companies, investors and industrial and pharmaceutical companies,
- **Pitch sessions** in front of a panel of experts for 25 innovative European healthcare companies selected by European clusters and associations,
- **Conferences and round tables** led by international opinion leaders.

About HealthTech For Care

The HealthTech For Care endowment fund is designed to support and promote access to healthcare for all, and in particular to new medical technologies and medicines. The endowment fund's missions are three-fold: to support the development of the entire healthcare ecosystem, to accelerate the development of innovative therapies and medicines, and to promote better patient access to the healthcare system in France and Europe.

HealthTech For Care is governed by Maryvonne Hiance, Elsy Boglioli, Pierre Courteille, Marc Dechamps, Christian Deleuze, Eric Falcand, Frédéric Girard, Marc Julien, Anaïs Le Corvec, Bernard Linsmeau, Cédric Moreau, Christian Pierret and Christian Policard.

https://www.linkedin.com/company/healthtech-for-care/ https://htfc-eu.com

About HealthTech Innovation Days

HealthTech Innovation Days (HTID[®]), initiated by France Biotech and implemented by the HealthTech For Care endowment fund, provides a forum for all stakeholders in the life sciences to meet and bring innovation to patients. Each year, HTID brings together over 800 participants in Paris. The 5th edition will take place on October 24 and 25, 2023 in Paris, and on October 27 in virtual form only. https://htfc-eu.com/htid/

Press contacts

HTFC Nathalie Donne <u>nathalie.donne@htfc-eu.com</u> +33(0)6 67 67 44 97 HTFC Solène Goupy <u>solene.goupy@htfc-eu.com</u> +33(0)6 38 03 80 19